Ultragenyx Pharmaceutical Inc.

For the period ended Jun 30, 2025. Filed Aug 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 6, 2025

RARE$16.41+6.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2025	2024	2025	2024
Revenues:
Product sales	$80,817	$73,805	$172,324	$136,294
Royalty revenue	85,679	73,221	133,464	119,565
Total revenues	166,496	147,026	305,788	255,859
Operating expenses:
Cost of sales	23,002	21,280	51,664	38,813
Research and development	164,736	161,503	330,508	339,990
Selling, general and administrative	86,646	80,604	174,443	158,764
Total operating expenses	274,384	263,387	556,615	537,567
Loss from operations	(107,888)	(116,361)	(250,827)	(281,708)
Interest income	5,794	7,401	12,625	16,225
Change in fair value of equity investments	(9)	(3,991)	(166)	(245)
Non-cash interest expense on liabilities for sales of future royalties	(14,041)	(15,960)	(28,383)	(31,807)
Other income (expense)	2,140	(1,829)	2,977	(3,434)
Loss before income taxes	(114,004)	(130,740)	(263,774)	(300,969)
Provision for income taxes	(947)	(858)	(2,257)	(1,313)
Net loss	$(114,951)	$(131,598)	$(266,031)	$(302,282)
Net loss per share, basic and diluted	$(1.17)	$(1.52)	$(2.73)	$(3.54)
Shares used in computing net loss per share, basic and diluted	98,460,445	86,580,516	97,381,745	85,433,443

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.